Source-grounded facts extracted from Taysha Gene Therapies, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Taysha Gene Therapies, Inc. shareholders approved Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-06-01 meeting.
“Proposal No. 4 : Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 360,924 630,378 67,607 Broker Non-Votes: 38,973,186”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-01 meeting.
“Proposal No. 3 : Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 36,396,784 345,291 Broker Non-Votes: 38,973,186”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-01 meeting.
“Proposal No. 2 : Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 25,551 18,176 Broker Non-Votes: 0”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-01 meeting.
“Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 169,142,295 35,742,331 Laura Sepp-Lorenzino, Ph.D. 150,094,517 54,790,109 Broker Non-Votes: 38,973,186 Both nominees were elected.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 6, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2026, and recent business highlights.”
Governance Changes
Taysha Gene Therapies, Inc.: Increase in authorized common stock from 400,000,000 to 700,000,000 (effective 2025-06-02).
“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Amendment ”) to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for Full Year 2023.
“On March 19, 2024, Taysha Gene Therapies, Inc. (the " Company ") reported financial results for the year ended December 31, 2023 and recent business and clinical updates.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.